Why in News: The World Health Organization prequalified CERVAVAC, the Serum Institute of India’s quadrivalent human papillomavirus (HPV) vaccine, in early October 2026 — the first India-made HPV vaccine to get WHO prequalification and the company’s 32nd prequalified product. It protects against HPV types 6, 11, 16 and 18 and is licensed for both girls and boys aged 9 to 26. Prequalification allows UN agencies such as UNICEF and Gavi to buy it for other countries.
Why It Matters
- Cervical cancer is almost entirely caused by persistent infection with high-risk HPV types (16 and 18 cause about 70% of cases).
- India bears about a fifth of the world’s cervical cancer burden — around 1.2 lakh new cases and over 75,000 deaths a year — and it is the second most common cancer among Indian women.
- Affordability: imported HPV vaccines cost several thousand rupees a dose; an Indian vaccine priced far lower makes national programmes feasible.
- Global supply: WHO prequalification helps fill a chronic global shortage of HPV vaccines for low-income countries.
India’s Programme
- The government announced HPV vaccination for girls aged 9–14 under the Universal Immunisation Programme (Interim Budget 2024); rollout is being phased in with State campaigns.
- WHO (2022) recommends that a single dose can be used for girls aged 9–14, which cuts cost and logistics.
- Screening: visual inspection with acetic acid (VIA) and HPV-DNA tests under the national NCD screening programme for women aged 30–65.
Concerns
- Hesitancy and misinformation (including the 2010 trial controversy in Andhra Pradesh and Gujarat by PATH).
- Reaching out-of-school girls; including boys (gender-neutral vaccination) to reduce HPV transmission and other cancers.
Static Background — Vaccines and Cervical Cancer
- CERVAVAC was developed by the Serum Institute with support from the Department of Biotechnology and BIRAC; launched in 2023.
- Quadrivalent: protects against four HPV types — 16 and 18 (cancer-causing), 6 and 11 (genital warts).
- WHO Cervical Cancer Elimination Initiative (2020): “90-70-90” targets for 2030 — 90% of girls vaccinated by age 15, 70% of women screened by ages 35 and 45, 90% of women with disease treated; elimination means under 4 cases per 1 lakh women.
- WHO prequalification: certifies quality, safety and efficacy so that UN agencies can procure the product.
- Universal Immunisation Programme (1985): free vaccines against 12 diseases; Mission Indradhanush (2014) to raise coverage; U-WIN digital registry (2024).
| Target (WHO, by 2030) | Level |
|---|---|
| Girls fully vaccinated by age 15 | 90% |
| Women screened with a high-performance test by ages 35 and 45 | 70% |
| Women with disease receiving treatment | 90% |
Exam Angle — Prelims & Mains
- UPSC PYQ Link: Prelims has asked about viral diseases and vaccines (e.g., which diseases are caused by viruses).
- Practice Mains Question (GS Paper 2, 10 marks, 150 words): An affordable indigenous HPV vaccine makes the elimination of cervical cancer achievable in India. Discuss the challenges in achieving the WHO’s 90-70-90 targets.
- Prelims Angle: HPV types, quadrivalent meaning and prequalification.
- Practice Prelims MCQ 1: Consider the following statements about CERVAVAC:1. It is a quadrivalent vaccine against HPV types 6, 11, 16 and 18.2. It is licensed only for girls.3. It has received WHO prequalification.Which of the statements given above are correct?(A) 1 and 2 only(B) 2 and 3 only(C) 1 and 3 only(D) 1, 2 and 3
Show answer
Answer: (C) 1 and 3 only — Statement 1 is CORRECT and Statement 3 is CORRECT. Statement 2 is INCORRECT — it is licensed for boys and girls aged 9–26. - Practice Prelims MCQ 2: Under the WHO Cervical Cancer Elimination Initiative, a country is considered to have eliminated cervical cancer when the incidence falls below:(A) 4 cases per 1 lakh women(B) 10 cases per 1 lakh women(C) 1 case per 10,000 women(D) 20 cases per 1 lakh women
Show answer
Answer: (A) — The threshold is fewer than 4 new cases per 100,000 women per year.
- Practice Prelims MCQ 1: Consider the following statements about CERVAVAC: